Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
{{output}}
Introduction: The understanding of atopic dermatitis (AD) pathogenesis has rapidly expanded in recent years, catalyzing the development of new targeted monoclonal antibody treatments for AD. ... ...
